Treatment-related adverse events of antibody drug-conjugates in clinical trials

Abstract Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 tri...

Full description

Saved in:
Bibliographic Details
Main Authors: Harold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, Anna Minchom, Adam Sharp, Alec Paschalis, Georgina Silva-Fortes, Bindu Raobaikady, Udai Banerji
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:https://doi.org/10.1186/s13045-025-01720-3
Tags: Add Tag
No Tags, Be the first to tag this record!